Skip to main content

Selected Publications


Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Fig. 3. CLL-CI correlates with EFS in patient subgroups (validation set).</p> ... Full text Cite

Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 2. CLL-CI correlates with OS across CLL patient subgroups (derivation dataset).</p> ... Full text Cite

Data from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <div>AbstractPurpose:<p>Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied.</p>Experimental Des ... Full text Cite

Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 1. CIRS correlates with outcomes in CLL (derivation dataset).</p> ... Full text Cite

Data from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <div>AbstractPurpose:<p>Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied.</p>Experimental Des ... Full text Cite

Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 2. CLL-CI correlates with OS across CLL patient subgroups (derivation dataset).</p> ... Full text Cite

Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 1. CIRS correlates with outcomes in CLL (derivation dataset).</p> ... Full text Cite

Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Fig. 3. CLL-CI correlates with EFS in patient subgroups (validation set).</p> ... Full text Cite

Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Fig. 3. CLL-CI correlates with EFS in patient subgroups (validation set).</p> ... Full text Cite

Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 2. CLL-CI correlates with OS across CLL patient subgroups (derivation dataset).</p> ... Full text Cite

Data from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <div>AbstractPurpose:<p>Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied.</p>Experimental Des ... Full text Cite

Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 1. CIRS correlates with outcomes in CLL (derivation dataset).</p> ... Full text Cite

Data from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <div>AbstractPurpose:<p>Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied.</p>Experimental Des ... Full text Cite

Supplementary Fig 2 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 2. CLL-CI correlates with OS across CLL patient subgroups (derivation dataset).</p> ... Full text Cite

Supplementary Fig 1 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Figure 1. CIRS correlates with outcomes in CLL (derivation dataset).</p> ... Full text Cite

Supplementary Fig 3 from The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

Other · March 31, 2023 <p>Supplemental Fig. 3. CLL-CI correlates with EFS in patient subgroups (validation set).</p> ... Full text Cite

Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study.

Journal Article J Geriatr Oncol · January 2023 INTRODUCTION: Chronic lymphocytic leukemia (CLL) is the most common incurable leukemia/lymphoma in the United States. Individuals with CLL are at risk for disability, frailty, and cancer-specific complications that negatively affect health-related quality ... Full text Link to item Cite

CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?

Journal Article Clin Lymphoma Myeloma Leuk · October 2022 CONTEXT: Ibrutinib and other Bruton-tyrosine kinase inhibitors (BTKi) have transformed treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and improved overall survival. However, cardiovascular and other non-CLL progression rel ... Full text Link to item Cite

Racial differences in venous thromboembolism: A surveillance program in Durham County, North Carolina.

Journal Article Res Pract Thromb Haemost · July 2022 BACKGROUND: Venous thromboembolism (VTE) affects approximately 1-2 individuals per 1000 annually and is associated with an increased risk for pulmonary hypertension, postthrombotic syndrome, and recurrent VTE. OBJECTIVE: To determine risk factors, incidenc ... Full text Link to item Cite

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.

Journal Article JACC CardioOncol · June 2022 There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or c ... Full text Open Access Link to item Cite

Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia.

Journal Article Front Oncol · 2022 Many patients with chronic lymphocytic leukemia (CLL) experience physical dysfunction and low overall fitness. It remains unknown what factors drive CLL physical dysfunction. We assessed physical function and metabolic lipoprotein panels in 106 patients wi ... Full text Link to item Cite

A pilot study of high-intensity interval training in older adults with treatment naïve chronic lymphocytic leukemia.

Journal Article Sci Rep · November 30, 2021 Chronic lymphocytic leukemia (CLL) is the most common leukemia in the USA, affecting predominantly older adults. CLL is characterized by low physical fitness, reduced immunity, and increased risk of secondary malignancies and infections. One approach to im ... Full text Link to item Cite

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

Journal Article Clin Cancer Res · September 1, 2021 PURPOSE: Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied. EXPERIMENTAL DESIGN: We conducted a retrospective analysis f ... Full text Link to item Cite

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Journal Article Blood · May 20, 2021 Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in chronic lymphocytic leukemia (CLL). Umbralisib, a novel highly selective phosphatidylinositol 3-kinase δ (PI3Kδ)/CK1ε inhibitor, is active and well tolerated in CLL patients ... Full text Link to item Cite

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL).

Journal Article Cells · May 2021 Chronic lymphocytic leukemia (CLL) is associated with physical dysfunction and low overall fitness that predicts poor survival following the commencement of treatment. However, it remains unknown whether higher fitness provides antioncogenic effects. We id ... Full text Cite

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

Journal Article Blood Adv · August 25, 2020 Although novel agents (NAs) have improved outcomes for patients with chronic lymphocytic leukemia (CLL), a subset will progress through all available NAs. Understanding outcomes for potentially curative modalities including allogeneic hematopoietic stem ce ... Full text Link to item Cite

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.

Journal Article Clin Cancer Res · July 15, 2020 PURPOSE: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. EXPERIMENTAL DESIGN: ... Full text Link to item Cite

Impact of exercise on the immune system and outcomes in hematologic malignancies.

Journal Article Blood advances · April 2020 Exercise is increasingly recognized as important to cancer care. The biology of how exercise improves outcomes is not well understood, however. Studies show that exercise favorably influences the immune system in healthy individuals (neutrophils, monocytes ... Full text Cite

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Journal Article Clin Cancer Res · July 15, 2019 PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of se ... Full text Link to item Cite

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Journal Article Blood Adv · May 28, 2019 Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, re ... Full text Link to item Cite

Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches.

Journal Article Appl Clin Inform · May 2019 BACKGROUND: Systematic surveillance for venous thromboembolism (VTE) in the United States has been recommended by several organizations. Despite adoption of electronic medical records (EMRs) by most health care providers and facilities, however, systematic ... Full text Link to item Cite

Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Journal Article J Geriatr Oncol · March 2019 OBJECTIVE: To explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer. METHODS: Eligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemother ... Full text Link to item Cite

Health-Related Quality of Life: The Impact on Morbidity and Mortality.

Journal Article Surg Oncol Clin N Am · October 2018 In the age of ever-expanding treatments and precision medicine, the hope for cure remains the ultimate goal for patients and providers. Equally important to many patients is the quality of life achieved during and after treatment. Evidence suggests that ov ... Full text Link to item Cite

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Journal Article Haematologica · September 2018 Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treat ... Full text Link to item Cite

Preliminary program evaluation of emergency department HIV prevention counseling.

Journal Article Ann Emerg Med · July 2011 OBJECTIVE: Controversy surrounds the linkage of prevention counseling with emergency department (ED)-based HIV testing. Further, the effectiveness and feasibility of prevention counseling in the ED setting is unknown. We investigate these issues by conduct ... Full text Link to item Cite